Regine Schneider-Stock
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Regine Schneider-Stock has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
Albert Roessner
12 shared publicationsCarsten Boltze
7 shared publicationsA. Roessner
5 shared publicationsBrigitte Peters
Biometrics, and
4 shared publications- Albert Roessner
Institute of Pathology, Otto-von-Guericke University, 39120 Magdeburg, Germany
3 shared publications Kathrin Radig
Otto-von-Guericke University, Department of Pathology, Leipziger Str. 44, D-39120 Magdeburg, GermanyTel.: +49 391 67 15060 Fax: +49 391 67 15818
3 shared publications
Latest Publications
- 31 May 2009
- Published by Elsevier in Gastroenterology
- Vol. 136 (5)
S1959 Silencing of CHFR By Loss of DNA Copy Numbers and Promoter Hypermethylation in Esophageal Adenocarcinoma
- 31 May 2009
- Published by Elsevier in Gastroenterology
- Vol. 136 (5)
S1959 Silencing of CHFR By Loss of DNA Copy Numbers and Promoter Hypermethylation in Esophageal Adenocarcinoma
- 1 August 2007
- Vol. 10 (8) , 557-61
Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.
The past decades have brought major breakthroughs in the identification of distinct genetic alterations (eg, mutations, chromosomal aberrations) in various human tumors, leading to the development and clinical use of novel target-specific antibodies and small molecules. Recently, variable modifications of chromatin elements have become the focus of cell biology research. Compounds that inhibit the key chromatin-modifying enzyme classes of histone deacetylase (HDAC) and DNA methyltransferase (DNMT) are currently being evaluated in various preclinical studies and clinical trials. The overexpression of both HDAC and DNMT has been demonstrated to be associated with the epigenetic inactivation of tumor suppressor genes, as well as cell cycle and apoptosis regulators. In addition, inhibitors of HDAC and DNMT possess direct cytotoxic properties, and can sensitize tumor cells to conventional radiotherapy and chemotherapy.
- 1 August 2007
- Vol. 10 (8) , 557-61
Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.
The past decades have brought major breakthroughs in the identification of distinct genetic alterations (eg, mutations, chromosomal aberrations) in various human tumors, leading to the development and clinical use of novel target-specific antibodies and small molecules. Recently, variable modifications of chromatin elements have become the focus of cell biology research. Compounds that inhibit the key chromatin-modifying enzyme classes of histone deacetylase (HDAC) and DNA methyltransferase (DNMT) are currently being evaluated in various preclinical studies and clinical trials. The overexpression of both HDAC and DNMT has been demonstrated to be associated with the epigenetic inactivation of tumor suppressor genes, as well as cell cycle and apoptosis regulators. In addition, inhibitors of HDAC and DNMT possess direct cytotoxic properties, and can sensitize tumor cells to conventional radiotherapy and chemotherapy.
- 1 September 2005
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 37 (9) , 1763-1767
DAP-kinase—Protector or enemy in apoptotic cell death
- 1 September 2005
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 37 (9) , 1763-1767
DAP-kinase—Protector or enemy in apoptotic cell death
- RetractedOpen Access
- 1 February 2005
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 312 (2) , 525-536
RETRACTION: 5-aza-Cytidine Is a Potent Inhibitor of DNA Methyltransferase 3a and Induces Apoptosis in HCT-116 Colon Cancer Cells via Gadd45- and p53-Dependent Mechanisms
Methyltransferase inhibitors commonly used in clinical trials promote tumor cell death, but their detailed cytotoxic action is not yet fully understood. A deeper knowledge about their apotosis-inducing mechanisms and their interaction with DNA methyltransferases (DNMTs) DNMT1, DNMT3a, and DNMT3b might allow the design of more effective drugs with lower cytotoxicity. 5-aza-cytidine (5-aza-CR), a potent inhibitor of DNMT1, is known to induce demethylation and reactivation of silenced genes. In this study, we investigated the p53 dependence of apoptotic, cell cycle, and growth inhibitory effects of 5-aza-CR, as well as the influence on the expression level of DNMT1, DNMT3a, and DNMT3b in the colon cancer cell line HCT-116. Exposure to 5-aza-CR induced the up-regulation of genes promoting cell cycle arrest and DNA repair (p21WAF1 and GADD45) or apoptosis (p53, RIPK2, Bak1, caspase 5, and caspase 6). In parallel, there was a down-regulation of antiapoptotic Bcl2 protein and the G2/M-mediator cyclin B1. Co-incubation with pifithrin-alpha (PFT-α), a selective p53 inhibitor, restored GADD45, Bcl2, cyclin B1, and p21WAF1 expression levels and almost completely reversed the growth inhibitory, cell cycle, and apoptotic effects of 5-aza-CR. 5-aza-CR treatment caused global demethylation and reactivation of p16INK4 expression. There was a marked decrease in DNMT1 and DNMT3a mRNA expression, with PFT-α reversing these effects. However, 5-aza-CR treatment did not modulate DNMT3b expression. Our data demonstrate that 5-aza-CR action in HCT-116 is mediated by p53 and its downstream effectors p21WAF1 and GADD45. This is the first report to show a link between p53 and regulation of DNMT1 and de novo methyltransferase DNMT3a.
- 1 February 2005
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 312 (2) , 525-536
RetractedOpen AccessRETRACTION: 5-aza-Cytidine Is a Potent Inhibitor of DNA Methyltransferase 3a and Induces Apoptosis in HCT-116 Colon Cancer Cells via Gadd45- and p53-Dependent Mechanisms
Methyltransferase inhibitors commonly used in clinical trials promote tumor cell death, but their detailed cytotoxic action is not yet fully understood. A deeper knowledge about their apotosis-inducing mechanisms and their interaction with DNA methyltransferases (DNMTs) DNMT1, DNMT3a, and DNMT3b might allow the design of more effective drugs with lower cytotoxicity. 5-aza-cytidine (5-aza-CR), a potent inhibitor of DNMT1, is known to induce demethylation and reactivation of silenced genes. In this study, we investigated the p53 dependence of apoptotic, cell cycle, and growth inhibitory effects of 5-aza-CR, as well as the influence on the expression level of DNMT1, DNMT3a, and DNMT3b in the colon cancer cell line HCT-116. Exposure to 5-aza-CR induced the up-regulation of genes promoting cell cycle arrest and DNA repair (p21WAF1 and GADD45) or apoptosis (p53, RIPK2, Bak1, caspase 5, and caspase 6). In parallel, there was a down-regulation of antiapoptotic Bcl2 protein and the G2/M-mediator cyclin B1. Co-incubation with pifithrin-alpha (PFT-α), a selective p53 inhibitor, restored GADD45, Bcl2, cyclin B1, and p21WAF1 expression levels and almost completely reversed the growth inhibitory, cell cycle, and apoptotic effects of 5-aza-CR. 5-aza-CR treatment caused global demethylation and reactivation of p16INK4 expression. There was a marked decrease in DNMT1 and DNMT3a mRNA expression, with PFT-α reversing these effects. However, 5-aza-CR treatment did not modulate DNMT3b expression. Our data demonstrate that 5-aza-CR action in HCT-116 is mediated by p53 and its downstream effectors p21WAF1 and GADD45. This is the first report to show a link between p53 and regulation of DNMT1 and de novo methyltransferase DNMT3a.
- Open Access
- 15 January 2005
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (2) , 638-645
Loss of p16 Protein Defines High-Risk Patients with Gastrointestinal Stromal Tumors: A Tissue Microarray Study
Despite clearly defined histologic criteria, the prediction of tumor behavior for patients with gastrointestinal stromal tumors (GIST) still poses a challenge to pathologists. Therefore, searching for alternative markers that allow for better prognostic evaluation is an important task. To determine the practicability of immunohistochemical staining for p16 in clinical cases, we examined p16 protein expression in a group of 284 GISTs, a subset of which had long-term follow-up (median, 45 months; range, 1-204 months). P16 protein expression was ascertained on tissue microarrays as well as on standard sections. Survival analyses were carried out in 157 patients. P16 loss was found in 50% of GISTs, there being no correlation with age, sex, histologic subtype, signs of necrosis, or metastases. Patients having p16-negative tumors had a worse prognosis than those with p16-positive tumors (P = 0.012) with a 2.3-fold relative increased risk of dying of disease. P16 loss identified a subgroup of gastric tumors with a worse prognosis (P = 0.03). The multivariate configural frequency analysis identified two “antitypes,” whose observed frequency was found to be significantly lower than the expected frequency [i.e., marker combinations: p16 positive, no metastases, and death of disease and p16 loss, metastases, and still alive]. The “type” whose observed frequency was significantly higher than the expected frequency consisted of the following marker pattern: p16 loss, necrosis, and death of disease (P < 0.001). In the multivariate Cox regression analysis, p16 loss, necrosis, and metastases each had independent prognostic value. P16 loss is a common molecular abnormality in GISTs and might be used in routine diagnosis to identify patients with high-risk tumors.
- 15 January 2005
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (2) , 638-645
Open AccessLoss of p16 Protein Defines High-Risk Patients with Gastrointestinal Stromal Tumors: A Tissue Microarray Study
Despite clearly defined histologic criteria, the prediction of tumor behavior for patients with gastrointestinal stromal tumors (GIST) still poses a challenge to pathologists. Therefore, searching for alternative markers that allow for better prognostic evaluation is an important task. To determine the practicability of immunohistochemical staining for p16 in clinical cases, we examined p16 protein expression in a group of 284 GISTs, a subset of which had long-term follow-up (median, 45 months; range, 1-204 months). P16 protein expression was ascertained on tissue microarrays as well as on standard sections. Survival analyses were carried out in 157 patients. P16 loss was found in 50% of GISTs, there being no correlation with age, sex, histologic subtype, signs of necrosis, or metastases. Patients having p16-negative tumors had a worse prognosis than those with p16-positive tumors (P = 0.012) with a 2.3-fold relative increased risk of dying of disease. P16 loss identified a subgroup of gastric tumors with a worse prognosis (P = 0.03). The multivariate configural frequency analysis identified two “antitypes,” whose observed frequency was found to be significantly lower than the expected frequency [i.e., marker combinations: p16 positive, no metastases, and death of disease and p16 loss, metastases, and still alive]. The “type” whose observed frequency was significantly higher than the expected frequency consisted of the following marker pattern: p16 loss, necrosis, and death of disease (P < 0.001). In the multivariate Cox regression analysis, p16 loss, necrosis, and metastases each had independent prognostic value. P16 loss is a common molecular abnormality in GISTs and might be used in routine diagnosis to identify patients with high-risk tumors.
- 1 April 2004
- Published by Elsevier in The American Journal of Pathology
- Vol. 164 (4) , 1233-1241
Retention of the Arginine Allele in Codon 72 of the p53 Gene Correlates with Poor Apoptosis in Head and Neck Cancer
- 1 April 2004
- Published by Elsevier in The American Journal of Pathology
- Vol. 164 (4) , 1233-1241
Retention of the Arginine Allele in Codon 72 of the p53 Gene Correlates with Poor Apoptosis in Head and Neck Cancer
- 1 May 2003
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (9) , 1688-1697
High Prognostic Value of p16INK4 Alterations in Gastrointestinal Stromal Tumors
Purpose: Gastrointestinal stromal tumors (GISTs) represent a distinctive (but histologically heterogeneous) group of neoplasms, the malignant potential of which is often uncertain. To determine the prognostic relevance of p16INK4 alterations in GISTs, we investigated a larger group of GISTs and correlated the genetic findings with clinicopathological factors and patient survival. Material and Methods: We evaluated the methylation status of the promotor by methylation-specific polymerase chain reaction (PCR), the presence of mutations by PCR-SSCP-sequencing, the loss of heterozygosity at the p16INK4 locus (using the c5.1 marker), and the immunohistochemical expression of p16INK4 protein in 43 GISTs in 39 patients. Results: p16INK4 alterations were found in 25 of 43 GISTs (58.1%), with benign, borderline, or malignant GISTs showing no differences in the type and frequency of alteration. p16INK4 alterations were correlated with a loss of p16INK4 protein expression (P < .01). Patients who had tumors with p16INK4 alterations had a poorer prognosis than patients with tumors without such alterations (P = .02). There was a high predictive value for p16INK4 alterations only in the group of benign and borderline GISTs (P < .01) with regard to clinical outcome. Univariate Cox’s proportional hazard regression analysis revealed a strong correlation between p16INK4 alterations, tumor size, mitotic index, and overall survival (P < .02), whereas multivariate Cox’s analysis confirmed only p16INK4 alterations as an independent prognostic factor. Conclusion: We believe that the evaluation of p16INK4 alteration status is a helpful prognosticator, particularly in the benign and borderline groups of GISTs.
- 1 May 2003
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (9) , 1688-1697
High Prognostic Value of p16INK4 Alterations in Gastrointestinal Stromal Tumors
Purpose: Gastrointestinal stromal tumors (GISTs) represent a distinctive (but histologically heterogeneous) group of neoplasms, the malignant potential of which is often uncertain. To determine the prognostic relevance of p16INK4 alterations in GISTs, we investigated a larger group of GISTs and correlated the genetic findings with clinicopathological factors and patient survival. Material and Methods: We evaluated the methylation status of the promotor by methylation-specific polymerase chain reaction (PCR), the presence of mutations by PCR-SSCP-sequencing, the loss of heterozygosity at the p16INK4 locus (using the c5.1 marker), and the immunohistochemical expression of p16INK4 protein in 43 GISTs in 39 patients. Results: p16INK4 alterations were found in 25 of 43 GISTs (58.1%), with benign, borderline, or malignant GISTs showing no differences in the type and frequency of alteration. p16INK4 alterations were correlated with a loss of p16INK4 protein expression (P < .01). Patients who had tumors with p16INK4 alterations had a poorer prognosis than patients with tumors without such alterations (P = .02). There was a high predictive value for p16INK4 alterations only in the group of benign and borderline GISTs (P < .01) with regard to clinical outcome. Univariate Cox’s proportional hazard regression analysis revealed a strong correlation between p16INK4 alterations, tumor size, mitotic index, and overall survival (P < .02), whereas multivariate Cox’s analysis confirmed only p16INK4 alterations as an independent prognostic factor. Conclusion: We believe that the evaluation of p16INK4 alteration status is a helpful prognosticator, particularly in the benign and borderline groups of GISTs.
- 1 January 2003
- Published by Elsevier in Pathology - Research and Practice
- Vol. 199 (6) , 445-450
Different mRNA Expression Profile During Tumor Progressionin a Well-differentiated Liposarcoma – A Microdissection Approach
- 1 January 2003
- Published by Elsevier in Pathology - Research and Practice
- Vol. 199 (6) , 445-450
Different mRNA Expression Profile During Tumor Progressionin a Well-differentiated Liposarcoma – A Microdissection Approach